drugset
drugset / Trial / NCT02695212

Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa

NCT02695212 ↗

Phase 2 Completed 20 enrolled Florida Academic Dermatology Centers
NaSingle-groupOpen-labelOther

Summary

The primary objective of this study is to evaluate the safety and efficacy of Apremilast in subjects with moderate Hidradenitis Suppurativa (HS).

Timeline

Start
2016-07
Primary completion
2017-08
Completion
2017-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Apremilast Small molecule 30 mg Oral

Indications

hidradenitis suppurativa